IP Library Granted Patent US 9,353,133
Granted Patent B2
US 9,353,133 · App. 14/201,459 · Granted May 31, 2016

Boron-containing small molecules

Inventors: Stephen J. Baker (Mountain View, CA); Tsutomu Akama (Sunnyvale, CA); Michael Richard Kevin Alley (Santa Clara, CA); Stephen J. Benkovic (College, PA); Michael DiPierro (Wadsworth, IL); Vincent S. Hernandez (Watsonville, CA); Karin M. Hold (Belmont, CA); Isaac Kennedy (Bolingbrook, IL); Igor Likhotvorik (Wilmette, IL); Weimin Mao (Sunnyvale, CA); Kirk Maples (San Jose, CA); Jacob J. Plattner (Orinda, CA); Fernando Rock (Los Altos, CA); Virginia Sanders (San Francisco, CA); Aaron M. Stemphoski (Florence, SC); George Petros Yiannikouros (Florence, SC); Siead Zegar (Orlando Park, IL); Yong-Kang Zhang (San Jose, CA); Huchen Zhou (Shanghai, CN)
Assignee: Anacor Pharmaceuticals, Inc.
C07F5/04A61K31/69A61K31/70A61K31/7076C07F5/025C07H19/06C07H19/16C07H21/00C07H23/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,353,133
App. No.
14/201,459
Granted
May 31, 2016
Kind
B2
Abstract

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Claims (25)

1. A compound, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:

in which

R 1 and R 2 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

wherein R 1 and R 2 , together with the atoms to which they are attached, can be optionally joined to form a 4- to 7-membered ring;

Z1 is a member selected from

wherein

R 3a and R 4a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R 5 is a member selected from halogen and OR 8

wherein

R 8 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl

R 9a is H, R 11a is H, R 12a is H, R 10a is substituted or unsubstituted phenyloxy, or substituted or unsubstituted pyridinyloxy.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl

and wherein R 1 and R 2 , together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane and substituted or unsubstituted dioxaborepane.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 , together with the atoms to which they are joined, form a member selected from dioxaborolane, substituted or unsubstituted tetramethyldioxaborolane, substituted or unsubstituted phenyldioxaborolane, dioxaborinane, dimethyldioxaborinane and dioxaborepane.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z1 is a member selected from

and R 5 is a member selected from substituted or unsubstituted methoxy, substituted or unsubstituted ethoxy, substituted or unsubstituted methoxymethoxy, substituted or unsubstituted ethoxyethoxy and substituted or unsubstituted tetrahydro-2H-pyran-2-yloxy.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 3a is H and R 4a is a member selected from methyl, ethyl, propyl, butyl, phenyl, benzyl and cyano.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 are each members independently selected from H, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, phenyl and benzyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are each members independently selected from H, methyl, isopropyl, and phenyl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are methyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are isopropyl.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are H.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from:

Assignments (2)
CHANGE OF NAME Recorded Nov 1, 2023
From: ANACOR PHARMACEUTICALS, INC.
To: ANACOR PHARMACEUTICALS, LLC
Reel/Frame 065427/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2015
From: BAKER, STEPHEN J.; AKAMA, TSUTOMU; ALLEY, MICHAEL RICHARD KEVIN; BENKOVIC, STEVEN J.; DIPIERRO, MICHAEL; HERNANDEZ, VINCENT S.; HOLD, KARIN M.; KENNEDY, ISAAC; LIKHOTVORIK, IGOR; MAO, WEIMIN; MAPLES, KIRK R.; PLATTNER, JACOB J.; ROCK, FERNANDO; SANDERS, VIRGINIA; STEMPHOSKI, AARON M.; YIANNIKOUROS, GEORGE PETROS; ZEGAR, SIEAD; ZHANG, YONG-KANG; ZHOU, HUCHEN
To: ANACOR PHARMACEUTICALS, INC.
Reel/Frame 034963/0754 →
Continuity (8)
Continuation 13356488 · Jan 23, 2012
Continuation 12629753 · Dec 2, 2009
Division 11505591 · Aug 16, 2006
Continuation In Part 11357687 · Feb 16, 2006
Provisional Application 60746361 · May 3, 2006
Provisional Application 60755227 · Dec 30, 2005
Provisional Application 60654060 · Feb 16, 2005
Related Publication 20140221631A1 · Aug 7, 2014